Integrated Proteomic and Metabolomic prediction of Term Preeclampsia

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Bahado Singh, Ray ^a   Poon, Liona C ^b,c   Yilmaz, Ali ^a   Syngelaki, Argyro ^b   Turkoglu, Onur ^a   Kumar, Praveen ^a   Kirma, Joseph ^d   Allos, Matthew ^d   Accurti, Veronica ^b   Li, Jiansheng ^e   Zhao, Peng ^e   Graham, Stewart F ^a   Cool, David R ^f   Nicolaides, Kypros ^b  

^a Beaumont Health ^*  (United States)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^d OAKLAND UNIVERSITY   (United States)

^e HENAN UNIVERSITY OF CHINESE MEDICINE   (China)

^f WRIGHT STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; FEMALE; GENETICS; HUMAN; MATRIX-ASSISTED LASER DESORPTION-IONIZATION MASS SPECTROMETRY; METABOLISM; METABOLOMICS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PREECLAMPSIA; PREGNANCY; PROCEDURES; PROTEOMICS; RECEIVER OPERATING CHARACTERISTIC; TANDEM MASS SPECTROMETRY;

ADULT; FEMALE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; METABOLOMICS; PRE-ECLAMPSIA; PREGNANCY; PROTEOMICS; ROC CURVE; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TANDEM MASS SPECTROMETRY;

EID: 85034840760     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-15882-9     Document Type: Article

References (60)

1. Ananth, C. V., Keyes, K. M. & Wapner, R. J. Pre-eclampsia rates in the United States, 1980-2010: age-period-cohort analysis. Bmj 347, f6564, https://doi.org/10.1136/bmj.f6564 (2013).
2. Ogge, G. et al. Placental lesions associated with maternal underperfusion are more frequent in early-onset than in late-onset preeclampsia. Journal of perinatal medicine 39, 641-652, https://doi.org/10.1515/jpm.2011.098 (2011).
3. Lisonkova, S. & Joseph, K. S. Incidence of preeclampsia: risk factors and outcomes associated with early-versus late-onset disease. Am J Obstet Gynecol 209, 544.e541-544.e512, https://doi.org/10.1016/j.ajog.2013.08.019 (2013).
4. Crovetto, F. et al. First trimester screening for early and late preeclampsia based on maternal characteristics, biophysical parameters, and angiogenic factors. Prenatal diagnosis 35, 183-191 (2015).
5. Parra-Cordero, M. et al. Prediction of early and late pre-eclampsia from maternal characteristics, uterine artery Doppler and markers of vasculogenesis during first trimester of pregnancy. Ultrasound in Obstetrics & Gynecology 41, 538-544 (2013).
6. von Dadelszen, P., Magee, L. A. & Roberts, J. M. Subclassification of preeclampsia. Hypertens Pregnancy 22, 143-148, https://doi. org/10.1081/prg-120021060 (2003).
7. Lykke, J. A. et al. Hypertensive pregnancy disorders and subsequent cardiovascular morbidity and type 2 diabetes mellitus in the mother. Hypertension 53, 944-951, https://doi.org/10.1161/hypertensionaha.109.130765 (2009).
8. Behrens, I. et al. Association between hypertensive disorders of pregnancy and later risk of cardiomyopathy. Jama 315, 1026-1033 (2016).
9. Syngelaki, A. et al. Metformin versus Placebo in Obese Pregnant Women without Diabetes Mellitus. New England Journal of Medicine 374, 434-443, https://doi.org/10.1056/NEJMoa1509819 (2016).
10. Force, U. S. P. S. T. Screening for preeclampsia: Us preventive services task force recommendation statement. JAMA 317, 1661-1667, https://doi.org/10.1001/jama.2017.3439 (2017).
11. Plasencia, W., Maiz, N., Poon, L., Yu, C. & Nicolaides, K. H. Uterine artery Doppler at 11 + 0 to 13 + 6 weeks and 21 + 0 to 24 + 6 weeks in the prediction of pre-eclampsia. Ultrasound in obstetrics & gynecology: the official journal of the International Society of Ultrasound in Obstetrics and Gynecology 32, 138-146, https://doi.org/10.1002/uog.5402 (2008).
12. Wright, A., Guerra, L., Pellegrino, M., Wright, D. & Nicolaides, K. H. Maternal serum PAPP-A and free beta-hCG at 12, 22 and 32 weeks' gestation in screening for pre-eclampsia. Ultrasound in obstetrics & gynecology: the official journal of the International Society of Ultrasound in Obstetrics and Gynecology 47, 762-767, https://doi.org/10.1002/uog.15849 (2016).
13. Lai, J., Syngelaki, A., Poon, L. C., Nucci, M. & Nicolaides, K. H. Maternal serum soluble endoglin at 30-33 weeks in the prediction of preeclampsia. Fetal diagnosis and therapy 33, 149-155, https://doi.org/10.1159/000343220 (2013).
14. Valino, N., Giunta, G., Gallo, D. M., Akolekar, R. & Nicolaides, K. H. Biophysical and biochemical markers at 35-37 weeks' gestation in the prediction of adverse perinatal outcome. Ultrasound in obstetrics & gynecology: the official journal of the International Society of Ultrasound in Obstetrics and Gynecology 47, 203-209, https://doi.org/10.1002/uog.15663 (2016).
15. Lai, J., Poon, L. C., Bakalis, S., Chiriac, R. & Nicolaides, K. H. Systolic, diastolic and mean arterial pressure at 30-33 weeks in the prediction of preeclampsia. Fetal diagnosis and therapy 33, 173-181, https://doi.org/10.1159/000345950 (2013).
16. Andrietti, S., Silva, M., Wright, A., Wright, D. & Nicolaides, K. H. Competing-risks model in screening for pre-eclampsia by maternal factors and biomarkers at 35-37 weeks' gestation. Ultrasound in obstetrics & gynecology: the official journal of the International Society of Ultrasound in Obstetrics and Gynecology 48, 72-79, https://doi.org/10.1002/uog.15812 (2016).
17. German, J. B., Hammock, B. D. & Watkins, S. M. Metabolomics: building on a century of biochemistry to guide human health. Metabolomics 1, 3-9, https://doi.org/10.1007/s11306-005-1102-8 (2005).
18. Bahado-Singh, R. O. et al. First-trimester metabolomic detection of late-onset preeclampsia. American journal of obstetrics and gynecology 208, 58. e51-58. e57 (2013).
19. Del Boccio, P. et al. Integration of metabolomics and proteomics in multiple sclerosis: From biomarkers discovery to personalized medicine. Proteomics. Clinical applications 10, 470-484, https://doi.org/10.1002/prca.201500083 (2016).
20. Fahrmann, J. F. et al. Integrated metabolomics and proteomics highlight altered nicotinamide and polyamine pathways in lung adenocarcinoma. Carcinogenesis, https://doi.org/10.1093/carcin/bgw205 (2017).
21. Ma, Y. et al. An integrated proteomics and metabolomics approach for defining oncofetal biomarkers in the colorectal cancer. Annals of surgery 255, 720-730 (2012).
22. Karnovsky, A. et al. Metscape 2 bioinformatics tool for the analysis and visualization of metabolomics and gene expression data. Bioinformatics 28, 373-380 (2012).
23. Kenneth, L., Hall, D. R., Gebhardt, S. & Grove, D. Late onset preeclampsia is not an innocuous condition. Hypertension in pregnancy 29, 262-270 (2010).
24. Kenny, L. C. et al. Robust early pregnancy prediction of later preeclampsia using metabolomic biomarkers. Hypertension 56, 741-749, https://doi.org/10.1161/hypertensionaha.110.157297 (2010).
25. Kuc, S. et al. Metabolomics profiling for identification of novel potential markers in early prediction of preeclampsia. PLoS One 9, e98540, https://doi.org/10.1371/journal.pone.0098540 (2014).
26. Carty, D. M. et al. Urinary proteomics for prediction of preeclampsia. Hypertension 57, 561-569, https://doi.org/10.1161/ HYPERTENSIONAHA.110.164285 (2011).
27. Myers, J. E. et al. Integrated proteomics pipeline yields novel biomarkers for predicting preeclampsia. Hypertension 61, 1281-1288, https://doi.org/10.1161/HYPERTENSIONAHA.113.01168 (2013).
28. Amirshahrokhi, K., Bohlooli, S. & Chinifroush, M. M. The effect of methylsulfonylmethane on the experimental colitis in the rat. Toxicology and applied pharmacology 253, 197-202, https://doi.org/10.1016/j.taap.2011.03.017 (2011).
29. Butawan, M., Benjamin, R. L. & Bloomer, R. J. Methylsulfonylmethane: Applications and Safety of a Novel Dietary Supplement. Nutrients 9, https://doi.org/10.3390/nu9030290 (2017).
30. Mohammadi, S. et al. Protective effects of methylsulfonylmethane on hemodynamics and oxidative stress in monocrotaline-induced pulmonary hypertensive rats. Advances in pharmacological sciences 2012, 507278, https://doi.org/10.1155/2012/507278 (2012).
31. de Luca Brunori, I. et al. Increased HLA-DR homozygosity associated with pre-eclampsia. Human Reproduction 15, 1807-1812 (2000).
32. de Luca Brunori, I. et al. HLA-DR in couples associated with preeclampsia: background and updating by DNA sequencing. Journal of reproductive immunology 59, 235-243 (2003).
33. Small, H. Y. et al. Hla gene expression is altered in whole blood and placenta from women who later developed preeclampsia. Physiological Genomics, https://doi.org/10.1152/physiolgenomics.00106.2016 (2017).
34. Steinborn, A., Rebmann, V., Scharf, A., Sohn, C. & Grosse-Wilde, H. Soluble HLA-DR levels in the maternal circulation of normal and pathologic pregnancy. Am J Obstet Gynecol 188, 473-479 (2003).
35. Small, H. Y. et al. HLA gene expression is altered in whole blood and placenta from women who later developed preeclampsia. Physiol Genomics 49, 193-200, https://doi.org/10.1152/physiolgenomics.00106.2016 (2017).
36. Zheng, H. et al. Association between polymorphism of the G-protein beta3 subunit C825T and essential hypertension: an updated meta-analysis involving 36,802 subjects. Biological research 46, 265-273, https://doi.org/10.4067/s0716-97602013000300007 (2013).
37. Kvehaugen, A. S. et al. Single nucleotide polymorphisms in G protein signaling pathway genes in preeclampsia. Hypertension 61, 655-661, https://doi.org/10.1161/hypertensionaha.111.00331 (2013).
38. McGuane, J. T. & Conrad, K. P. GPCRs as potential therapeutic targets in preeclampsia. Drug Discovery Today: Disease Models 9, e119-e127 (2012).
39. Rozengurt, E., Sinnett-Smith, J. & Kisfalvi, K. Crosstalk between Insulin/IGF-1 and GPCR Signaling Systems: A Novel Target for the Anti-diabetic Drug Metformin in Pancreatic Cancer. Clinical cancer research: an official journal of the American Association for Cancer Research 16, 2505-2511, https://doi.org/10.1158/1078-0432.ccr-09-2229 (2010).
40. Bolte, A. C., van Geijn, H. P. & Dekker, G. A. Pathophysiology of preeclampsia and the role of serotonin. European Journal of Obstetrics & Gynecology and Reproductive Biology 95, 12-21, https://doi.org/10.1016/S0301-2115(00)00367-5 (2001).
41. Nagatomo, T., Rashid, M., Muntasir, H. A. & Komiyama, T. Functions of 5-HT 2A receptor and its antagonists in the cardiovascular system. Pharmacology & therapeutics 104, 59-81 (2004).
42. Famá, E. A. B., Souza, R. S., Melo, C. M., Pompei, L. M. & Pinhal, M. A. S. Evaluation of glycosaminoglycans and heparanase in placentas of women with preeclampsia. Clinica Chimica Acta 437, 155-160 (2014).
43. Bahado-Singh, R. O. et al. Metabolomics and first-trimester prediction of early-onset preeclampsia. The journal of maternal-fetal & neonatal medicine 25, 1840-1847 (2012).
44. Kelly, R. S. et al. Integration of metabolomic and transcriptomic networks in pregnant women reveals biological pathways and predictive signatures associated with preeclampsia. Metabolomics 13, 7 (2017).
45. Bieberich, E. Synthesis, processing, and function of N-glycans in N-glycoproteins. Advances in neurobiology 9, 47-70, https://doi. org/10.1007/978-1-4939-1154-7-3 (2014).
46. Shannon, K. F.-N. et al. Aberrant Glycosylation of Plasma Proteins in Severe Preeclampsia Promotes Monocyte Adhesion. Reproductive Sciences 21, 204-214, https://doi.org/10.1177/1933719113492210 (2014).
47. Wang, F., Wang, L., Shi, Z. & Liang, G. Comparative N-Glycoproteomic and Phosphoproteomic Profiling of Human Placental Plasma Membrane between Normal and Preeclampsia Pregnancies with High-Resolution Mass Spectrometry. PLOS ONE 8, e80480, https://doi.org/10.1371/journal.pone.0080480 (2013).
48. Robajac, D. et al. Preeclampsia transforms membrane N-glycome in human placenta. Experimental and Molecular Pathology 100, 26-30, https://doi.org/10.1016/j.yexmp.2015.11.029 (2016).
49. Poon, L. C., Kametas, N. A., Valencia, C., Chelemen, T. & Nicolaides, K. H. Hypertensive disorders in pregnancy: screening by systolic diastolic and mean arterial pressure at 11-13 weeks. Hypertens Pregnancy 30, 93-107, https://doi.org/10.3109/10641955.20 10.484086 (2011).
50. Mercier, P., Lewis, M., Chang, D., Baker, D. & Wishart, D. Towards automatic metabolomic profiling of high-resolution onedimensional proton NMR spectra. J Biomol NMR 49, 307-323, https://doi.org/10.1007/s10858-011-9480-x (2011).
51. Hilario, M., Kalousis, A., Pellegrini, C. & Mueller, M. Processing and classification of protein mass spectra. Mass spectrometry reviews 25, 409-449 (2006).
52. Broadhurst, D. I. & Kell, D. B. Statistical strategies for avoiding false discoveries in metabolomics and related experiments. Metabolomics 2, 171-196 (2006).
53. Xia, J., Broadhurst, D. I., Wilson, M. & Wishart, D. S. Translational biomarker discovery in clinical metabolomics: an introductory tutorial. Metabolomics: Official journal of the Metabolomic Society 9, 280-299, https://doi.org/10.1007/s11306-012-0482-9 (2013).
54. Tibshirani, R. Regression Shrinkage and Selection via the Lasso. Journal of the Royal Statistical Society. Series B (Methodological) 58, 267-288 (1996).
55. Hastie, T., Tibshirani, R. & Friedman, J. H. The Elements of Statistical Learning: Data Mining, Inference, and Prediction. (Springer, 2001).
56. Xia, J., Mandal, R., Sinelnikov, I. V., Broadhurst, D. & Wishart, D. S. MetaboAnalyst 2.0-a comprehensive server for metabolomic data analysis. Nucleic acids research 40, W127-133, https://doi.org/10.1093/nar/gks374 (2012).
57. Xia, J., Psychogios, N., Young, N. & Wishart, D. S. MetaboAnalyst: a web server for metabolomic data analysis and interpretation. Nucleic acids research 37, W652-660, https://doi.org/10.1093/nar/gkp356 (2009).
58. Xia, J., Sinelnikov, I. V., Han, B. & Wishart, D. S. MetaboAnalyst 3.0-making metabolomics more meaningful. Nucleic acids research 43, W251-257, https://doi.org/10.1093/nar/gkv380 (2015).
59. Kamburov, A., Cavill, R., Ebbels, T. M. D., Herwig, R. & Keun, H. C. Integrated pathway-level analysis of transcriptomics and metabolomics data with IMPaLA. Bioinformatics 27, 2917-2918 (2011).
60. Wishart, D. S. et al. HMDB: the Human Metabolome Database. Nucleic acids research 35, D521-526, https://doi.org/10.1093/nar/ gkl923 (2007).